Background: Mastopexy and reduction mammaplasty are often limited by the patient's poor native soft tissue quality, resulting in ptosis recurrence and loss of rejuvenated surgical results. Surgical scaffolds and acellular dermal matrices are used in these procedures to provide physical and mechanical stabilization of weakened or compromised tissue. GalaFLEX scaffold, made from poly-4-hydroxybutyrate (P4HB), is a next-generation product for soft tissue reinforcement that resorbs gradually while aiding tissue regeneration to achieve excellent outcomes. Objectives: To assess the clinical performance of GalaFLEX scaffold in soft tissue reinforcement during elective mastopexy and reduction mammaplasty. Methods: This multicenter, single-arm, observational study assessed product performance and outcomes of GalaFLEX scaffold when used in breast surgery. Outcomes included ptosis correction and maintenance, associated adverse events, patient and surgeon satisfaction, and mammographic and ultrasound imaging evaluation. Results: At 6 centers in the US, 62 of 69 enrolled patients were treated. Of this population, 89.7% had successful ptosis correction and maintenance at 1 year, with high patient and surgeon satisfaction for breast shape, droop/sag of the breast, and maintenance of results at 1 year. There were 5 adverse events deemed related to the device (8.0%), including nerve pain, breast swelling, ptosis, and 2 instances of asymmetry. Conclusions: GalaFLEX scaffold safely and successfully supports and elevates breast tissue in mastopexy and reduction mammaplasty, with maintained support at 1 year. Surgeon and patient satisfaction were high. No mammogram or ultrasound interference was detected.
Plastic surgery procedures performed on weakened and/or deficient tissues are common. Although skin laxity can be addressed in mastopexy and breast reduction, the underlying deficiency and weakness of the soft tissues remain unchanged, even after a successful surgery. For this reason, soft tissue support products have been considered for these procedures for many years. However, there has been a lack of clinical data to demonstrate the impact of these products over time.
A breast is considered ptotic if the nipple-areola complex (NAC) is even with or below the inframammary fold (IMF). 1 Aging, pregnancy, macromastia, and weight loss can contribute to ptosis, although it can be found in patients of all ages and all breast sizes. In the breast, ptosis is categorized by grade according to the severity of the inferior displacement of the breast parenchyma, based on Regnault's classification ( Figure 1 ). 1, 2 For over 35 years, different types of sutures, meshes, and scaffolds have been used in cosmetic surgery procedures to repair and reinforce soft tissue. 3 Góes has reported various permanent and resorbable scaffolds used in his mammaplasty procedure that incorporate a double skin technique. 4 Furthermore, he has specifically conveyed that early support is observed with the use of meshes with short-term resorption profiles, including VICRYL mesh; however, following resorption, he reported recurrent ptosis. 5 In later work, Góes recommended the use of a more permanent prosthetic (60% polyglactin and 40% polyester composite) based on the resorption of the fibrotic supporting layer and the subsequent weakening leading to recurrent ptosis. 4 Góes currently recommends VYPRO mesh, a hybrid mesh that consists of woven polypropylene (nonresorbable) and polyglactin (resorbed in 6 weeks); however, he has emphasized the need for a fully resorbable support system that will last through the formation of a stable scar. 4, 5 The GalaFLEX scaffold (Galatea Surgical, Inc; Lexington, MA) is a fully resorbable, monofilament scaffold made from poly-4-hydroxybutyrate (P4HB). P4HB belongs to a family of naturally occurring biopolymers called polyhydroxyalkanoates (PHAs). P4HB is produced through a biological fermentation process similar to that used for pharmaceutical production. 3 P4HB degrades into the natural metabolite 4-hydroxybutyrate (4HB), which has a halflife of 27 minutes in the body. 4HB is catabolized via the Krebs cycle and is eliminated as water and carbon dioxide.
Made from P4HB monofilament fibers, the GalaFLEX scaffold has a macroporous, knitted design that mitigates the potential for unraveling when the scaffold is cut. Use of a monofilament design in surgical meshes has been shown to decrease infection risk and promote wound healing. 3 GalaFLEX scaffold provides immediate strength for reinforcing soft tissue throughout the critical wound-healing phase, maintaining approximately 50% of its strength at 16 weeks. The open pore design acts as a lattice to promote tissue ingrowth and remodeling over time. The scaffold is rapidly vascularized and becomes fully integrated with the adjacent tissue, with resorption essentially complete in 18 to 24 months. 3 In contrast, VICRYL (Ethicon US, LLC; Somerville, NJ) multifilament sutures rapidly degrade, losing 50% of their strength within 3 weeks and are completely resorbed at 70 days postprocedure. 3 PDS II (Ethicon US, LLC; Somerville, NJ) monofilament sutures can provide longer-lasting support, but little residual strength remains at approximately 8 weeks. MONOCRYL (Ethicon US, LLC; Somerville, NJ) monofilament sutures also degrade rapidly, and retain only approximately 50% of the initial strength at 1 week and are completely resorbed by 119 days postprocedure.
Due to the need for stronger, longer-lasting soft tissue reinforcement, the use of P4HB scaffolds has become an important tool used in a variety of aesthetic breast surgeries. The purpose of this study was to assess the clinical performance of GalaFLEX scaffold in soft tissue reinforcement during elective (cosmetic) mastopexy and reduction mammaplasty by assessing ptosis correction and associated adverse events, patient and surgeon satisfaction, and the detection of any interference in mammography or ultrasound results due to the scaffold. An initial report of the first 11 patients of this study was recently published, with findings suggesting that central mound mastopexy with soft tissue reinforcement in the lower pole leads to a stable result for at least 1 year following surgery. 6 
METHODS

Study Design
This multicenter, prospective, single-arm, observational study assessed the product performance and outcomes of GalaFLEX scaffold when used for support and reinforcement in breast surgery. Procedures were performed in 6 centers (locations) by a group of 6 plastic surgeons (W.P.A., B.W.V., C.G., R.B., M.T., and B.A.M.). This study was conducted according to principles of good clinical practice. All patients signed consent forms prior to the performance of any study procedures, in accordance with guidelines set forth by the Western Institutional Review Board (WIRB).
The initial purpose of the study protocol was to assess physician preference in the clinical performance of GalaFLEX scaffold in soft tissue reinforcement during elective (cosmetic) plastic surgery to the breast, in particular breast lift mastopexy and breast reduction procedures. In order to provide a more clinically relevant outcome, the primary analysis was modified in the Statistical Analysis Plan (SAP) to assess the clinical performance of GalaFLEX scaffold in soft tissue reinforcement during elective (cosmetic) plastic surgery to the breast, in particular breast lift (mastopexy) with or without reduction.
The primary outcome for study success was defined as a dual endpoint: ptosis correction and maintenance of the surgical correction, where correction of ptosis at 3 months must be grade 0, pseudoptosis, or grade I; and maintenance of ptosis correction at 1 year was demonstrated by a classification of ptosis grade I or less. For patients with a preprocedure ptosis grade of grade I, the grade at 3 and 12 months must be grade 0 or pseudoptosis to be considered successful. Any patients with a secondary breast intervention due to adverse events were considered failures for the primary outcome.
Additional outcomes included 3-dimensional (3D) imaging measurements of volume and lift based on changes between landmarks; investigator and patient satisfaction, evaluated through questionnaires/surveys; technical performance of the GalaFLEX scaffold via evaluation of ptosis resolution based on the change in nipple to IMF stretch distance and sternal to nipple distance using hand measurements pre-and postsurgery; and long-term visibility, evaluated via mammography and ultrasound to determine the potential for scaffold interference in evaluation of breast tissue.
Study Participants
Potential candidates were evaluated at a participating site and enrolled from July 2012 to September 2015. Exclusion criteria are listed in Table 1 . Demographic information, including age, body mass index, and smoking status were recorded for each patient. Patients underwent full evaluation, breast measurements, and 3D breast scanning prior to the procedure and at 1, 3, 6, and 12 months following surgery. In addition, breasts were measured by hand at each visit (nipple-to-inframammary fold, sternal notch-tonipple, clavicle-to-inframammary fold, and breast width).
Surgical Approach
Each patient underwent an outpatient surgical procedure using GalaFLEX scaffold for reinforcing tissue in the elective cosmetic breast procedure. Tissue dissection and mastopexy or reduction technique was determined by surgeon's best practice. The size of GalaFLEX scaffold used and procedures performed are detailed in Table 2 . Mastopexy was performed with or without reduction, with the surgeons defining the procedure type on case report forms. Based on the data obtained from these forms, 44 patients underwent mastopexy alone, breast reduction was performed in 10 patients, and 7 patients had both mastopexy and reduction. One patient (008-003) had breast augmentation in conjunction with the mastopexy procedure. The study was not intended to include augmentation cases, so this design intent was subsequently clarified with the investigators. The most common procedures were mastopexy -inferior pedicle (38.7%) and mastopexy -central mound (33.9%). The most common Figure 1 . Degrees of breast ptosis. In the breast, ptosis is categorized by grade, according to the severity of the inferior displacement of the breast parenchyma. 1 Grade I ptosis is the most mild form and consists of a nipple just below the IMF but still above the lower pole. Grade II ptosis is described by the nipple further below the IMF but still with some lower pole tissue below the nipple. Grade III is the most severe and is characterized as nipple placement well below the IMF with no lower pole tissue below the nipple. Pseudoptosis is commonly seen with postpartum breast atrophy and has the nipple at or above the IMF with inferior pole ptosis. size of GalaFLEX scaffold used for both breasts was 6 × 8 in. The scaffold was modified from its original size in over 70% of cases by shaping and cutting. In general, the mesh was used as a lower pole hammock with some variability based on investigator discretion. In 96.8% of cases, the mesh was sutured to the fascia/chest wall. In 98.4% of cases, the mesh was sutured to breast parenchyma laterally, located lower than the nipple complex. In 43.5% of cases, the breast was lifted and the pedicle overlapped or the gland tightened prior to suturing of the mesh. Various suture types were used to secure the mesh, including MonoMax, Vicryl, Monocryl, and PDS. Images of the procedure before and after scaffold placement are shown in Figures 2 and 3 
Patient Satisfaction
At baseline and at all time points following study procedures, patients were questioned regarding their satisfaction with the results. They reported how satisfied they were with breast sag and breast shape without clothes, and provided additional input on similar satisfaction queries. The patients filled out a 1-page questionnaire during their baseline and follow-up visits. The questionnaire was a case report form for the study (Appendix A). The same questionnaire was used at each time point. The patient completed the form independently, with no other person involved in asking the questions.
Surgeon Satisfaction
Surgeons completed questionnaires to assess the surgical procedures and determine the role mesh played in the perception of the surgeons' ability to obtain a successful result (Appendix A). The surgeons also reported their satisfaction with the performance of the scaffold and use characteristics.
Three-Dimensional Imaging and Analysis
Three-dimensional images were obtained at the preprocedure, 30-day, 90-day, 6-month, and 12-month time points as previously described, using the Canfield 3D or Vectra System, depending on site availability. 6 A photographer at the site was trained to position patients to reduce error for overlaying images. For each photograph, patients were instructed to place both hands on the anterior superior iliac spine and stand upright with their shoulders level. Images from the system were exported to Canfield for analysis. Images were not accessible by study site investigators and the technician was blinded to patient follow-up time points. Three-dimensional imaging was not used for outcome analysis, as Canfield equipment was not available at all clinical sites.
Statistical Analysis
An independent statistician performed all statistical analyses. Ptosis evaluation was summarized as the proportion of patients meeting the success criteria outlined above, including the number and percentage of patients in each category and the two-sided Clopper-Pearson 95% CI of the percentages. Landmark distances were compared at 
RESULTS
Patient Demographics
A total of 69 female patients were enrolled at 6 centers in the United States. The study was stopped for business reasons to limit both the duration and cost of the study prior to the enrollment of the original 100 planned patients. The study was not stopped for any safety issues. Per site enrollment is described in Table 3 . Of these, 7 patients were not treated, leaving 62 patients who underwent procedures with GalaFLEX scaffold and are included in the intent to treat (ITT) population ( Figure 4 ). The group's age ranged from 25.6 to 67.7 years, with an average of 42.4 ± 9.4 years (Supplemental Table 1 ). The women were predominantly white (96.8%) and had an average BMI of 24.7 ± 2.9 kg/m 2 (range, 20.0-34.7 kg/m 2 ). The majority of patients never smoked (80.6%; Table 4 ). Initial breast measurements are described in Supplemental Table 2 .
Adverse Events
Adverse events were reported and coded based on site-reported information, using Medical Dictionary Table 5 ). The device-related events included nerve pain treated with a steroid injection, mild breast swelling, ptosis, and 2 instances of asymmetry, 1 requiring scaffold removal and the other requiring scaffold release (loosening) to eliminate constriction of the breast. There was no indication that the breast swelling was a result of a seroma or inflammation, which are reported adverse reactions seen with surgical mesh products. It was a mild area of swelling medial to the vertical suture line and no intervention or treatment was required. The issue resolved within 2 weeks.
Only 1 event was reported as serious by the investigators, which was not related to the device or the procedure. This patient underwent a concomitant abdominoplasty and developed a wound infection related to this procedure. No GalaFLEX scaffold was used in the abdominal procedure.
An independent assessment of adverse events by a physician not associated with the study determined that a total of 8 adverse events could be defined as serious based on changes in patients' medical conditions that required intervention. These included 3 hematomas (resolved; related to mastopexy procedure), 1 case of delayed healing (not related to GalaFLEX scaffold), 1 removal of scaffold to address a surgical site infection, and 3 asymmetry corrections (scaffold was released in 2 cases and removed in 1 case to correct asymmetry).
Ptosis Correction and Maintenance
The majority of patients had moderate or advanced ptosis at baseline (grade I: 4.8%; grade II: 41.9%; grade III: 51.6%); however, at all follow-up assessments, the majority of patients had no ptosis. At 90 days, 66.1% of patients had no ptosis, 32.2% had grade I ptosis, and 1.7% had pseudoptosis; no patients had grade II or III ptosis ( Figure 5 ). Importantly, these results were maintained at 1 year, with 67.9% of patients having grade 0 ptosis, 3.6% having pseudoptosis, 25.0% having grade I ptosis, and only 2 patients having grade II ptosis. Evaluating the change from baseline measurements in patients with available data, 58/59 (98.3%) patients were improved at 90 days and 55/56 (98.2%)
were improved from baseline at 1 year. At 1 year, 52/56 (92.9%) maintained the improvement observed at the 90-day assessment. Representative photographs of patients before and after surgery are shown in Figures 6, 7 , and 8.
In the ITT population, the success for both correction and maintenance was 89.7% (95% CI 78.8%-96.1%). GalaFLEX placed in lower pole of the breast using an inferior pedicle technique (images courtesy of Dr Bruce Van Natta).
Complete information was available for 55 patients at both 90 and 365 days. According to primary outcome criteria, the failures included 2 patients who had grade II ptosis at 1 year, one of whom underwent a secondary intervention (a primary endpoint failure criteria) for removal of the scaffold due to an infection, and 4 patients who required secondary intervention to remove or release the scaffold for correction of asymmetry.
Patient Satisfaction
Typically, patients undergo cosmetic breast procedures because they are dissatisfied with their appearance. This patientive assessment may be used to determine the success of the procedure. At baseline, only 2 patients were satisfied with the shape of their breasts without clothes (Table 6) sag of her breasts without clothes (Supplemental Table 3 ). At both 90 days and 1 year, the proportion of patients satisfied with the droop/sag of their breasts without clothes improved to 98.3% (59/60) and 94.4% (51/54), respectively. At both 90 days and 1 year, the proportion of patients satisfied with the shape of their breasts without clothes improved to 93.3% (56/60) and 98.1% (52/53), respectively. The differences between satisfied and dissatisfied patients were significantly different at all time points (P < 0.0001 for all; Figure 9 ).
Physician Satisfaction
To determine the role GalaFLEX scaffold played in physician's perception of the ability to obtain a successful result, physicians provided assessments of the surgical procedures. In 61/62 cases, it was believed that the quality of the patient's skin envelope would have affected the long-term outcome had they not used GalaFLEX scaffold. Physicians were also asked about satisfaction with GalaFLEX scaffold performance and use characteristics. Responses reflected 83.9% to 98.4% satisfaction for most questions regarding GalaFLEX scaffold performance. At all time points, the rate of physician satisfaction regarding overall procedure results was significantly higher than dissatisfaction (P < 0.0001 for all; Supplemental Table 4 ). Furthermore, the rate of physician satisfaction regarding GalaFLEX scaffold prolonging procedure results reached 100% at 1 year, with significant differences from dissatisfaction rate at all time points (P < 0.0001 for all; Supplemental Table 5 ). Regarding palpability following the procedure and handling/suturing, physicians judged GalaFLEX scaffold to be better more than 90% of the time compared with other products (Table 7) . 
Visibility in Mammography and Ultrasound
Mammography and ultrasound assessments at 1 year postprocedure were conducted to determine the extent to which GalaFLEX scaffold interfered with breast imaging. At the 12-month follow-up visit, a subset of patients (32/56, 57.1%) had mammograms and 26/56 (46.4%) patients had ultrasounds performed. An independent radiologist performed a retrospective review of the breast mammograms and/or ultrasound images from 5 patients at 1 study site (Supplemental Table 6 ). A single reviewer was used to achieve consistent interpretation of the radiological images and to specifically comment on the appearance of the scaffold.
Per the radiologist's review, GalaFLEX scaffold was visible on the mammograms as a thin, 1 mm, subcutaneous radiopaque curvilinear line, and often thicker, up to 7 mm, at the posteromedial and/or posterolateral margins where it usually had a "wavy" configuration. The scaffold was most difficult to visualize in one patient with extremely dense breast tissue.
Per the independent review, 2 of the cases did not demonstrate any postoperative imaging abnormalities and were reported as Breast Imaging Reporting and Data System 1 (BI RADS 1): negative. There were 2 cases in which, on ultrasound, there were similar appearing thin, oval, hypoechoic structures in the lateral breast, both of which were palpable. These findings were occult on mammography. These structures were likely related to the scaffold, but without additional imaging (ie, breast MRI), it was impossible to be more definitive. As such, both cases were determined to be BI-RADS 3: probably benign.
Lastly, there was one case of postoperative focal architectural distortion involving the right breast, the differential diagnosis of which was postsurgical scar vs malignancy. Due to the location of this finding in the central to inferior position of the breast, it seems very unlikely that it was related to the scaffold itself. This was appropriately designated as BI-RADS 4B (moderately suspicious for malignancy). Overall, the scaffold did not interfere with the diagnostic quality of the mammograms. In addition, it was also reported by the reviewer that GalaFLEX scaffold was not generally visible on ultrasound and did not interfere with the diagnostic quality of the exams.
Three-Dimensional Imaging Analysis
Distances were calculated between defined landmarks using measurements of the surface distance along the breast from 3D images to define stretch or change over time ( Table 8 ). The stretch between the sternal notch, a fixed point, and the inferior breast point over the first year was 5.5% (1.5 cm), with the majority of stretch occurring between months 1 and 3 (0.9 cm, 3.4%). Looking at stretch from sternal notch to nipple, from month 3 to month 12, the stretch was 0.4% (0.1 cm).
Nipple Height and Projection
The nipple projection from the chest wall only changed 0.2 cm between month 1 and month 12, with a reduction of 0.1 cm from months 1 to 3 and from months 3 to 12, reflecting less than a 5% change overall (Table 8) .
Breast Volume and Volumetric Changes
An average reduction of 77.4 cc was observed from baseline to month 1, demonstrating volume reduction in all patients, regardless of the inclusion of a reduction procedure. Between months 1 and 3, the average postsurgical breast volume decreased by 32.5 cc, reflecting further reductions in swelling following the procedure. No significant total volume change was reported from month 3 to month 12. Between months 3 and 12, upper pole volume significantly decreased by an average of 11%, whereas lower pole volume significantly increased by 11.5%, reflecting a volume shift from upper pole to lower pole.
DISCUSSION
The current study demonstrates that GalaFLEX scaffold can be used successfully in mastopexy procedures to support the breast and to preserve the improvement through 1 year. Ptosis grade was improved at 90 days and maintained through 1 year. In the ITT population of the current study, the success for both correction and maintenance was 89.7% (95% CI 78.8%-96.1%). An overall lower pole stretch of 5% was measured by 3D analysis in the study group, which in a population of generally larger breasted patients, a greater stretch would be expected. The clinical observations of ptosis improvement and maintenance were supported by satisfaction results from both physicians and patients. There was no imaging interference due to the scaffold identified in postoperative mammograms.
Possible adverse reactions that have been observed with surgical scaffold products (and are included in product labeling) include infection, seroma, pain, scaffold migration, wound dehiscence, hemorrhage, adhesions, hematoma, inflammation, extrusion, and recurrence of the soft tissue defect. A low adverse event rate was seen in this study. Of the adverse events reported, some may be attributed to the lack of surgeon familiarity with GalaFLEX scaffold and the learning curve associated with any new procedure. GalaFLEX scaffold does not stretch; therefore, overcorrection to achieve the desired result is not necessary, as opposed to what is required with acellular dermal matrix products that stretch after implantation. As a result, surgical techniques must be adjusted accordingly. It was previously reported that in an early surgical case, the GalaFLEX scaffold was overtightened, which led to breast asymmetry requiring surgical correction. 8 In the current 
Rate your satisfaction with the mastopexy with GalaFLEX scaffold compared to a mastopexy procedure without GalaFLEX scaffold study, an adverse event of breast asymmetry was reported approximately 4 months following mesh implantation with a superior pedicle breast reduction. The surgeon stated that the lower pole of the breast was constricted and likely secondary to mesh placement. He felt the mesh had been placed too tightly and elected to remove the surgical mesh to correct the asymmetry. This is a known technical error and can be minimized with surgeon education. Study surgeons reported that their technique of implantation evolved over the course of the study. Anecdotally, the surgeons felt their later cases were more reliable. As the surgeons gained experience, they began to control the IMF fixation more vigorously. With experience, outcomes became more predictable.
In the current study, we reported no case in which the presence of GalaFLEX scaffold prevented overall interpretation of mammograms or ultrasound imaging.
Physician satisfaction was reported at all time points in terms of GalaFLEX scaffold performance, and significantly improved patient satisfaction was reported at all time points postprocedure. Because women choose to undergo these procedures because they are not satisfied with their appearance, high patient satisfaction is a crucial outcome. A recent study investigating augmentation mastopexy following bariatric surgery demonstrated 95% patient satisfaction following the procedure compared with 25% satisfaction preprocedure. 9 In the same study, surgeons rated the results of each patient, with 65% considered good or great, 26.6% considered average, and 8.4% considered poor. In our current study, all physicians were satisfied with the procedure results, demonstrating improved satisfaction rates among surgeons when GalaFLEX scaffold was implanted in elective mastopexy and reduction mammaplasty.
As a cosmetic procedure, the patient is always an engaged party; however, this does not guarantee patient satisfaction in all cosmetic surgery cases. Because there are inherent limitations in determining acceptable results in any cosmetic surgery, patient and surgeon satisfaction are important data to gather for assessing the success of a procedure.
Many cosmetic surgery studies have evaluated patient satisfaction. A recent study reported patient satisfaction regarding size, shape, projection, and natural appearance following augmentation mastopexy. 10 Zeiderman et al reported excellent outcomes based on patient satisfaction and surgeon judgment. 11 Van Deventer et al reported patient satisfaction outcomes with no discussion of the use of these outcomes as a limitation. 12 Fayman et al conducted a study based on patient satisfaction following periareola breast reduction. 13 Mizgala and MacKenzie also reported good results and high patient satisfaction. 14 Junior et al also conducted a study to evaluate surgical results and patient satisfaction following augmentation mastopexy. 9 According to Hamilton et al, patient satisfaction may be the most important criterion of success of clinical outcomes. 15 The difficulties regarding patient satisfaction surveys have been described, emphasizing caution of the use of validated measurements. 16 The questions we asked were not formally validated for measuring satisfaction; however, they were directed specifically toward aspects related to the surgical breast procedure. Satisfaction can be influenced significantly by clinical outcome, including the avoidance of complications and pain relief. 15 The most appropriate time point for evaluating patient satisfaction has not been elucidated.
The 3D imaging data presented from the ITT population (N = 62) are consistent with the previously published report on the first 11 patients. 6 However, because no previous studies have been conducted to specifically correlate 3D measurements with ptosis grades, one cannot conclude what level of stretch or quantitative value equates to an unacceptable result; correlation of the quantitative 3D values with what is observed clinically has not been done.
Most importantly, the 3D values become more meaningful when assessed in the context of clinical assessment of ptosis, the surgeon satisfaction, and the patient satisfaction scores. One cannot ascertain the significance of a value when no historical context exists, and without reviewing other sources of data, which would also be impacted by a change in ptosis. As this is the first large prospective study of its kind, these data create an initial baseline of values for future assessment and comparison.
This study had some limitations. The study did not include a control group; however, direct comparison to a control group would be met with significant issues due to the interindividual variability in breast volume and shape. Some physicians also felt that it would be unethical not to provide tissue support for a woman with suboptimal tissue quality. A randomized study for this patient population was initiated at a single center, but was closed due to poor enrollment, as patients universally desire the scaffold based on the resonance of increased support and shape. Importantly, the current study was designed to evaluate GalaFLEX scaffold performance and outcomes when used for support and reinforcement in elective mastopexy with or without breast reduction. The study was not designed to compare GalaFLEX scaffold with different materials; therefore, the design is appropriate.
There are very few published studies on the durability of breast lift surgeries, [17] [18] [19] [20] and none present this number of patients studied prospectively. Reus et al included 22 patients who were followed for an average of 4.7 years, revealing an increase in the distance between the inframammary fold to inferior areola distance. 17 Ahmad et al followed 46 women for 4 years, reporting a decreased distance from the inframammary crease to the inferior border of the nipple-areola complex over time. 18 Eder et al followed 26 patients who underwent inverted T-scar reduction mammaplasty and 22 patients who underwent vertical-scar reduction mammaplasty for 12 months following surgery, demonstrating a volumetric distribution change from the upper pole to the lower pole of the breast. 20 Small et al used 3D photography to assess 15 patients who underwent medial pedicle reduction mammaplasty at early (60-120 days) and late (400-500 days) time points, reporting a lower pole stretch of 21% at late time points. 21 In a subsequent publication, they reported significant changes in volume distribution, projection, and 3D topography throughout the first year following surgery, with minimal changes in postoperative years 2 and 3. 22 The current study included 62 patients who were followed for 1 year after undergoing elective surgical breast procedures. The lower pole stretch reported at 1 year was 5.5%, demonstrating an improvement in maintenance of results.
There are numerous pedicle techniques to achieve a good surgical outcome for mastopexy and reduction. 23 This study did not dictate a specific surgical technique and allowed the surgeons to utilize the technique that was determined to be best for the individual patient. Although no surgeons utilized a medial pedicle approach in this study, there is no identified technical reason to disallow use of GalaFLEX scaffold with this approach. As stated, the objective of the study was not to explore use of GalaFLEX scaffold with various surgical techniques, but to study clinical outcomes in a real-world setting.
This study is the first to gather data from both clinical assessment of ptosis and 3D imaging in mastopexy patients over a 12-month follow-up period. There are very few published studies on the durability of breast lift surgeries, and none present this number of patients studied prospectively. In our study, we evaluated the clinical outcome by using ptosis grading and, as a secondary measure, performed 3D imaging. These are two different approaches to assess the success and maintenance of a breast lift procedure. There are no accepted quantitative values from 3D imaging that have been correlated with ptosis grades or a change in grade based on Regnault's classification scale. In the analysis of data from 3D imaging from our study, the data show an approximate 5% change in distance between sternal notch and lowest point on the breast over 12 months, which is suggestive of acceptable maintenance of the ptosis correction. Correlation of 3D imaging was not an objective of the study, but is an area of opportunity for future studies.
Although this study is the first of its kind in plastic surgery, P4HB has been studied in other soft tissue support applications and longer-term follow-up data are available to suggest appropriate follow-up length to evaluate efficacy. As published by Deeken et al, a tissue plane develops concurrently with the resorption of the biomaterial, and this ingrown tissue provides mechanical support at the implant site. 24 Numerous clinical studies have recently been published or presented on use of surgical mesh manufactured with P4HB, including an ongoing clinical study in high-risk hernia repair patients with 18 months of follow up. 25 Based on data from 95 patients, device-related adverse events were low (9%), as were recurrence rate (9%) and reoperation rate (8%). The authors concluded that high-risk ventral and incisional hernia repair with Phasix mesh demonstrated positive outcomes and low incidence of hernia recurrence at 18 months.
Preclinical implantation studies indicate that the GalaFLEX scaffold retains approximately 70% of its strength at 12 weeks, 30% strength at 26 weeks, and essentially no strength at one year. Bioresorption of the scaffold material is essentially complete within 18 to 24 months; therefore, the local tissue primarily assumes mechanical support at the site of implantation, including the new ingrown tissue prior to the 12-month endpoint. The duration of the study has extended beyond the timeframe during which the mesh would be the primary source of mechanical support and therefore an understanding of efficacy can be ascertained at the 12-month endpoint of this study. A longer-term follow up would be informative; however, other confounding variables, such as patient weight gain and menopause, may influence endpoints.
In the current study, data regarding weight loss and parity, which are known to alter tissue quality and contribute to recurrent ptosis, were not collected during patient screening. Although we did not specifically collect data regarding massive weight loss preprocedure, one patient was known to have lost over 120 pounds prior to enrollment. We acknowledge that these parameters would provide additional insights in understanding the outcome measurements of the current study; however, recurrent ptosis was seldom seen during the course of this study.
The current study is a large, multicenter experience confirming and complementing the initial publication of a single center experience using GalaFLEX scaffold for mastopexy. This study provides important information and a greater potential application for the general patient population undergoing these cosmetic breast procedures. Moreover, as described, there is a paucity of data in the literature on mastopexy correction and maintenance of results; therefore, this prospective study provides useful clinical evidence in an area where little exists.
CONCLUSION
These results demonstrate the ability of GalaFLEX scaffold to support and elevate breast tissue in mastopexy and breast reduction procedures to achieve and maintain the desired surgical results. Specifically, there was a marked improvement in ptosis grade following healing from the surgical procedure (3 months) and this improvement was maintained through 1 year. With an 89.7% primary success rate in the ITT population with maintenance of results at 1 year, these data suggest a positive long-term outcome. Furthermore, both physician and patient satisfaction were high. These are critical findings for a cosmetic procedure wherein the initial procedure is performed because the patient is not satisfied with the appearance of her breasts. Surgical complications were infrequent and occurred at rates expected for patients undergoing similar procedures. No mammographic interference was identified. Overall, these findings support the safety and effectiveness of GalaFLEX scaffold when used as an adjunct in mastopexy procedures to reinforce lifted breast tissue.
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